We previously reported on the accumulation of a substantial amount of free N-acetylneuraminic acid (Neu5Ac)-containing complex-type N-glycans in human pancreatic cancer cells (Yabu M, Korekane H, Takahashi H, Ohigashi H, Ishikawa O, Miyamoto Y. 2013. Accumulation of free Neu5Ac-containing complex-type N-glycans in human pancreatic cancers. Glycoconj J, 30(3):247-256). In the present paper, we further extend our cancer glycomic study of human prostate cancer. Specifically, we demonstrate that, in addition to the free Neu5Ac-containing N-glycans, significant amounts of free deaminoneuraminic acid (KDN, 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid)-containing N-glycans had accumulated in the prostate cancer tissues from four of five patients. Indeed, in one of the four cases, the free KDN glycans accumulated as major components in prostate cancer tissue. The structures of the KDN-containing free oligosaccharides were analyzed by a variety of methods. Specifically, we used fluorescent labeling with aminopyridine combined with two-dimensional mapping, KDNase digestion and mass spectrometry to facilitate identification. The analysis also utilized newly synthesized KDN-linked oligosaccharides as standards. The prostate-specific glycans were composed of five species having the following sequence, KDN-GalGlcNAc-Man-Man-GlcNAc (α2,6-KDN-linked glycans being the dominant form). The most abundant free KDN-containing N-glycan was KDNα2-6Galβ1-4GlcNAcβ1-2Manα1-3Manβ1-4GlcNAc followed by KDNα2-6Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcNAc. This is the first study to show unequivocal chemical evidence for the occurrence of KDN glycoconjugates in human tissues together with their detailed structures. These oligosaccharides might be developed as tumor markers, especially for prostate cancer.
We previously reported on the accumulation of a substantial amount of free N-acetylneuraminic acid (Neu5Ac)-containing complex-type N-glycans in human pancreatic cancer cells (Yabu M, Korekane H, Takahashi H, Ohigashi H, Ishikawa O, Miyamoto Y. 2013 . Accumulation of free Neu5Ac-containing complex-type N-glycans in human pancreatic cancers. Glycoconj J, 30(3):247-256). In the present paper, we further extend our cancer glycomic study of human prostate cancer. Specifically, we demonstrate that, in addition to the free Neu5Ac-containing N-glycans, significant amounts of free deaminoneuraminic acid (KDN, 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid)-containing N-glycans had accumulated in the prostate cancer tissues from four of five patients. Indeed, in one of the four cases, the free KDN glycans accumulated as major components in prostate cancer tissue. The structures of the KDN-containing free oligosaccharides were analyzed by a variety of methods. Specifically, we used fluorescent labeling with aminopyridine combined with two-dimensional mapping, KDNase digestion and mass spectrometry to facilitate identification. The analysis also utilized newly synthesized KDN-linked oligosaccharides as standards. The prostate-specific glycans were composed of five species having the following sequence, KDN-GalGlcNAc-Man-Man-GlcNAc (α2,6-KDN-linked glycans being the dominant form). The most abundant free KDN-containing N-glycan was KDNα2-6Galβ1-4GlcNAcβ1-2Manα1-
Introduction
Remarkable alterations in oligosaccharide structures are associated with many human diseases, including cancers (Kim and Varki 1997; Brockhausen 1999; Hakomori 2002; Lau and Dennis 2008) . Numerous clinicopathological and biochemical studies have suggested the involvement of aberrant glycosylation in cancer malignancy, such as metastasis and invasion (Kannagi et al. 2004) . Furthermore, altered carbohydrate determinants, including tumor-associated carbohydrate antigens such as SLe a and SLe x , have been utilized as useful tumor markers for the diagnosis of cancer (Peracaula et al. 2008; Saldova et al. 2008) . Thus, cancer glycomic analyses have been widely used as a valuable tool to investigate the involvement of glycosylation in cancer malignancy as well as to find novel tumor marker candidates (Narimatsu et al. 2010; Alley et al. 2012) . We also have conducted accurate structural analysis of glycosphingolipids (GSLs) derived from colorectal cancers of more than 60 patients in our laboratory Shida et al. 2009 ). Our investigations identified alterations in the structures of GSLs related to cancers and established that these characteristic changes tend to be associated with specific clinical features such as hepatic metastasis. Moreover, sulfated GSLs were found to abnormally accumulate in colon cancers that were predicted to have low metastatic potential. We identified two kinds of novel tumorassociated carbohydrate antigens, Neu5Acα2-6(Fucα1-2) Galβ1-4GlcNAcβ1-3Galβ1-4Glc (α2,6-sialylated type 2H) and Neu5Acα2-6(Fucα1-2)Galβ1-3GlcNAcβ1-3Galβ1-4Glc (α2,6-sialylated type 1H), both of which are isomers of SLe a and SLe x (Korekane et al. 2007; Shida et al. 2010) , and α2,6-sialylated type 1H is specific to Lewis-negative patients. The evaluation of these two carbohydrate antigens as tumor markers is currently underway in our laboratory.
Furthermore, subsequent glycomic analyses revealed that large amounts of free Neu5Ac (N-acetylneuraminic acid)-containing complex-type N-glycans, almost all of which were the α2,6-Neu5Ac-linked form (with Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3Manβ1-4GlcNAc being the most abundant), were found to accumulate in pancreatic cancer tissue. However, the levels of free N-glycans in colorectal cancer cells and in normal colorectal and pancreatic tissues were barely detectable (Yabu et al. 2013) .
In the present study, we have extensively analyzed the structures of oligosaccharides in GSLs and free oligosaccharides derived from prostate cancers. These analyses revealed that, in addition to the free Neu5Ac-containing N-glycans accumulated in pancreatic cancer, a relatively large amount of free deaminoneuraminic acid (KDN, 2-keto-3-deoxy-Dglycero-D-galacto-nononic acid)-containing N-glycans were also found to accumulate in prostate cancers. With regard to KDN, refer to the review article by Inoue and Kitajima (2006) . KDN is an unusual type of sialic acid that was first discovered in the cortical alveolar polysialoglycoprotein of rainbow trout eggs (Nadano et al. 1986 ). Subsequent studies revealed that KDN, like the typical type sialic acid Neu5Ac, occurs widely among vertebrates and bacteria, although KDN is only abundant in lower vertebrates and pathogenic bacteria. In mammals, Neu5Ac occurs abundantly in both normal and tumor tissues, whereas KDN is almost undetectable . Until now, there have been few studies to show the unequivocal occurrence of KDN-containing glycoconjugates in human tissues or their precise structures. In this paper, the detailed structures of these free Neu5Ac-and KDN-containing complex-type N-glycans that accumulate in human prostate cancers are presented.
Results

Preparation of pyridylaminated oligosaccharides from human prostate cancers
We analyzed the structures of GSLs and free oligosaccharides of prostate cancer tissues derived from five patients (including a primary lesion and a bone metastatic lesion from the same patient). The clinicopathological features of the five prostate cancer patients are described in Supplementary data, Table S1 . It is well known that both free oligosaccharides and GSLs, but not glycoproteins, are recovered in lipid fractions from biological samples (Ishizuka et al. 2008) . In this study, both free oligosaccharides and GSLs were extracted from the tissues using organic solvent, chloroform/methanol. The oligosaccharide portions of GSLs were released by endoglycoceramidase II, and the reducing ends of the released oligosaccharides of GSLs and free oligosaccharides were tagged with the fluorophore, 2-aminopyridine (2-AP; Materials and methods). Authentic pyridylaminated (PA)-oligosaccharides required for the analysis of GSLs and free N-glycans are listed in Table I .
Major acidic free oligosaccharides accumulated in human prostate cancers The structures of neutral oligosaccharides derived from prostate cancers are not shown because these molecules did not display any interesting disease-related changes.
The acidic PA-oligosaccharides from prostate cancer tissues were analyzed by size-fractionation high-performance liquid chromatography (HPLC) ( Figure 1A-E) . Each of the peaks separated by the size-fractionation HPLC was further separated by reverse-phase HPLC. Additionally, the separated PA-oligosaccharides were subjected to liquid chromatography/ electrospray ionization MS/MS (LC/ESI MS 2 ) analysis. Some of the PA-oligosaccharides were also analyzed after digestion with glycosidase to help ascertain their structures. By means of these combinational analyses, the structures of all the major GSLs could be estimated and the occurrence of a large amount of free sialylated complex-type N-glycans in prostate cancers was unequivocally demonstrated. In total, 12 distinct sialylated free oligosaccharides (F1, F2, F3-1, F3-2, F4, F5-1, F5-2, F5-3, F5-4, F6, F7 and F8) were detected as major components in human prostate cancers (Figure 1 , Tables II and III). All these glycans were easily predicted to be sialylated free complex-type N-glycans having a single HexNAc (probably GlcNAc) at their reducing termini (Gn1 glycans) by mass analyses. Elution positions, mass data and estimated composition of the oligosaccharides are presented in Table II . Based on the composition of monosaccharides, we were able to classify the 12 free N-glycans into four groups as follows; group 1 (F3-1, F3-2, F4, F5-1 and F1), group 2 (F5-2, F5-3, F5-4, F6 and F7), group 3 (F8) and group 4 (F2) (Tables II and III ). In the following Results sections, the structures of these PA-oligosaccharides are described in detail.
Structural analyses of free sialylated complex-type N-glycans Groups 1, 3 and 4. Glycans of group 1 (F3-1, F3-2, F4, F5-1 and F1), group 3 (F8), and group 4 (F2) were free Neu5Ac-containing complex-type N-glycans (Table II) . All of these free glycans have been detected in human pancreatic cancer cells (Yabu et al. 2013) . Hence, the structures of most of these free glycans were estimated in the previous study and are listed in Table I as standard PA-oligosaccharides. From comparison of the positions on the map to the positions of standard PA-oligosaccharides, F1, F3-2, F4 and F8 are predicted to be Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3 Manβ1-4GlcNAc (N3M3), Neu5Acα2-6Galβ1-4GlcNAcβ1-2 Manα1-3Manβ1-4GlcNAc (N6M3), Neu5Acα2-6Galβ1-4GlcN Acβ1-2Manα1-6Manβ1-4GlcNAc (N6M6) and Neu5Acα2-6 Galβ1-4GlcNAcβ1-2Manα1-3(Manα1-6)Manβ1-4GlcNAc (N6M3(M6)), respectively ( Figure 2 ). The structures of these two-dimensional (2D) matched oligosaccharides were also confirmed by mass spectrometry. The structures of the remaining three free glycans, F3-1, F5-1 and F2, were unable to be unambiguously determined. F3-1 and F5-1 were thought to be either Neu5Acα2-6Galβ1-4GlcNAcβ1-6Manα1-6Man β1-4GlcNAc or Neu5Acα2-6Galβ1-4GlcNAcβ1-4Manα1-3 Manβ1-4GlcNAc. However, we were unable to unambiguously confirm this structure. Hence, the structures of F3-1 and F5-1 are given as Neu5Acα2-6Galβ1-4GlcNAcβ-Manα-Manβ1-4 GlcNAc, without the linkage position of the fourth GlcNAc and third Man residues from the reducing terminus (Table III) . F2 was predicted to have a LacdiNAc structure (GalNAcβ1-4GlcNAc) by mass analysis. The structure of F2 was thought to be Neu5Acα2-6GalNAc-GlcNAcβ-Manα-Manβ1-4GlcNAc, although the subterminal residue could not KDN-containing complex type N-glycans in prostate cancers be confirmed as GalNAc. F2 is given as Neu5Acα2-6Hex NAc-GlcNAcβ-Manα-Manβ1-4GlcNAc (Table III) .
Group 2. The MS 1,2 spectra of the five group 2 glycans (F5-2, F5-3, F5-4, F6 and F7) were essentially the same. A representative MS 1,2 spectrum of F5-3 is shown in Figure 3A and B. The structures of the group 2 free oligosaccharides were judged to be KDN-Gal-GlcNAc-Man-Man-GlcNAc-PA based on α-mannosidase digestion, MS 2 analysis and KDNase digestions ( Figure 3A and B). Specifically, (i) these oligosaccharides were completely resistant to α-mannosidase digestion, and thus, the probability of the branched structures, KDN-GlcNAc-Man-(Man-)Man-GlcNAc-PA, could be excluded; (ii) collision-induced dissociation spectra showed that the m/z 250 residue, which corresponded to KDN, was linked to the glycans ( Figure 3A and B) and (iii) the glycans could not be cleaved by N-acetylneuraminidase, but were digested by KDNase, which can digest deaminoneuraminyl but not N-acetylneuraminyl linkages. The KDNase digested products of F5-2, F5-3 and F7 co-migrated on the 2D map with the desialylated products of F3-1, F3-2 and F5-1, respectively (Figure 2A and B) . Similarly, the KDNase digested products of F5-4 and F6 co-migrated with desialylated F4 on the 2D map (Figure 2A and B) . Next, we determined the linkage positions of KDN for the five KDN glycans. First, α2,3-and α2,6-KDN-linked authentic N-glycans were enzymatically synthesized from the desialylated F3-1, F3-2, F4 and F5-1 by reaction with cytidine monophospho-KDN (CMP-KDN) catalyzed by α2,3-or α2,6-sialyltransferases. These N-glycans were then subjected to 2D mapping and mass analyses (see Material and methods, Figure 2C ). Our analyses revealed that KDN were linked α2-6 to F5-2, F5-3, F6 and F7 and α2-3 to F5-4 ( Figure 2C ). Therefore, the structures of F5-2, F5-3, F5-4, F6 and F7 were predicted as listed in Table III . As was the case for F3-1 and F5-1, the structures of F5-2 and F7 were deduced to be KDNα2-6Galβ1-4GlcNAcβ-Manα-Manβ1-4GlcNAc, without the linkage position of the fourth GlcNAc and third Man residues from the reducing terminus. Abbreviations of free N-linked glycans: N, M and K represent Neu5Ac, mannose, and KDN, respectively. Numbers mean the linkage position of Neu5Ac (N), third mannose (M) and KDN (K). M3 and M6 given in the parenthesis represent α1-3 and α1-6 mannose branches, respectively. Peak numbers shown in Figure 2 are given in parentheses.
Occurrence of both Neu5Ac-and KDN-containing free complex-type N-glycans in prostate cancer The structures of GSLs and free oligosaccharides from six prostate cancer tissues derived from five patients (including a primary lesion and a bone metastatic lesion from the same patient) have been analyzed. The prominent and striking feature of the profile of prostate cancer was the presence of relatively large amounts of free KDN-containing complex- Table S1 ); (C-E) Primary lesion from the other three patients (C, case 5; D, case 3; E, case 4; Supplementary data, Table S1 ). Eight major peaks derived from free N-glycans found in prostate cancers are represented as F1-F8 with fraction numbers as per Tables II and III . G1-G4 are the peaks derived from GSLs. The structures of G1-G4 are listed in Table I . The positions of minor peaks that were barely detectable are highlighted by either an arrowhead or an arrow. Table S1 ) contained KDN-linked free oligosaccharides as major components (shown in Figure 1A and B of the metastatic and primary lesion of this case) and prostate cancers from the other three cases (cases 3, 4 and 5, Supplementary data, Table S1 ) contained KDN-linked free oligosaccharides as minor components (shown in Figure 1C -E). Figure 1A shows the profiling of GSLs and free oligosaccharides from a bone metastatic lesion of a prostate cancer case (case 1) where a substantial amount of free KDN-containing N-glycans had accumulated. Two peaks, G1 (GM3) and G2 LS tetrasaccharide (LST-c), were obtained in acidic GSLs of this case. In addition to these GSLs, a variety of free oligosaccharides were also found as major components in this case. Six peaks, F2, F3, F4, F5, F6 and F7, corresponding to free N-glycans were observed. These peaks were much more prominent than those derived from GSLs, G1 (GM3) and G2 (LST-c). Reverse-phase HPLC revealed that peaks F2-F7 were composed of 10 glycans, F2, F3-1, F3-2, F4, F5-1, F5-2, F5-3, F5-4, F6 and F7. Among them, F5-2, F5-3, F5-4, F6 and F7 were classified as group 2 glycans, i.e. free KDN-containing N-glycans (Tables II and III) . The amount of each glycan is listed in Table III . We reported that almost all of the free N-glycans in human pancreatic cancers were composed of α2,6-Neu5Ac-linked glycans, with α2,3-sialylated glycans as minor species (Yabu et al. 2013) . As was the case of pancreatic cancer cells, α2,6-KDN-or α2,6-Neu5Ac-linked N-glycans are the dominant species (>98% in total free glycans). Intriguingly, the amount of each free α2,6-KDN-linked N-glycan is nearly equal or comparable with that of free α2,6-Neu5Ac-linked N-glycan, which has the same pentasaccharide backbone (Table III) . Namely, F3-2 and F5-3 are free α2,6-Neu5Ac-and α2,6-KDN-linked N-glycans, respectively, having the same pentasaccharide backbone, Galβ1-4GlcNAcβ1-2Manα1-3Manβ1-4-GlcNAc. The amount of F3-2 and F5-3 was 60 pmol/100 μg protein (i.e. 60.4 and 55.9 pmol/100 μg protein, respectively; Table III) . A similar pattern was observed for F4 and F6 (33.0 and 23.4 pmol/100 μg protein), F3-1 and F5-2 (22.9 and 20.8 pmol/100 μg protein) and F5-1 and F7 (3.5 and 7.7 pmol/100 μg protein), in which each pair has a common pentasaccharide backbone. The relative amount of free α2,6-Neu5Ac-and α2,6-KDN-containing N-glycans were as follows: F3-2 (25%) >> F4 (14%) >F3-1 (10%) > F5-1 (1%) and F5-3 (23%) >> F6 (10%) > F5-2 (9%) > F7 (3%) ( Table III) . The profiling of GSLs and free oligosaccharides of the primary prostate cancer lesion of this case is shown in Figure 1B . Although the ratio of KDN-linked free N-glycans was slightly lower than those of the metastatic lesion, profiles of free oligosaccharides from the two lesions, primary and metastatic, seem to be similar ( Figure 1A and B, Table III ).
The ratio of free KDN-containing oligosaccharides of the other three cases was much less than that of the previous case, as detailed below ( Figure 1C-E) . In the case (case 5, Supplementary data, Table S1) shown in Figure 1C , in group 1 and group 2 free N-glycans, four peaks, F3, F4, F5 and F6, 
Estimated structures and the amount of glycans in prostate cancer tissues (cases of Figure 1A -E) are presented. The amount of glycan is expressed as pmol/ 100 μg protein. (-) indicates that this glycan was not detected in the tissues.
composed of seven glycans, F3-1, F3-2, F4, F5-1, F5-2, F5-3 and F6, were observed ( Figure 1C ). The amount of free Neu5Ac-containing N-glycans, F3-1, F3-2, F4 and F5-1, was similar or comparable with those of the previous case shown in Figure 1A and B, but the amount of free KDN-containing N-glycans, F5-2, F5-3 and F6, was quite low (Table III) . Furthermore, F7, which was the major component of the previous case, was not found. In the cases shown in Figure 1D and E (cases 3 and 4, respectively, Supplementary data, Table S1 ), both Neu5Ac-containing and KDN-containing free N-glycans were much lower than those of the case shown in Figure 1A and B (Table III) . No correlation was found between the amounts of free oligosaccharides and the clinicopathological features of the four cases.
Discussion
We recently reported that large amounts of free Neu5Ac-containing complex-type N-glycans accumulate in pancreatic cancers (Yabu et al. 2013) . In contrast, only trace amounts of these N-glycans were detected in colorectal cancer tissue (Yabu et al. 2013) . Surprisingly, in addition to the free Neu5Ac-containing N-glycans, substantial amounts of free KDN-containing N-glycans were found to have accumulated in prostate cancers. To date, elevated expression of free KDN has been reported in fetal human red blood cells compared with adult red blood cells and ovarian tumor tissues compared with normal controls (Inoue et al. 1998) . KDN-rich glycoproteins were isolated from PA-1 cells, which were partially purified and characterized . Here, we demonstrate the substantial accumulation of KDN glycoconjugates in human prostate cancer tissues in the form of free complextype N-glycans. Moreover, the structures of these molecules have been investigated in detail.
The characteristic features of free Neu5Ac-and KDNcontaining N-glycans associated with human prostate cancers can be summarized as follows: (i) most of the free N-glycans were composed of α2,6-Neu5Ac-or α2,6-KDN-linked glycans, (ii) the branch on the α6-Man arm of biantennary N-glycans was preferentially removed. These features were also observed in the Neu5Ac-containing free N-glycans accumulated in human pancreatic and colorectal cancers (Yabu et al. 2013) . These data suggest a common mechanism among the various human cancers that underlies the accumulation of free complextype N-glycans.
Our findings raise three important questions concerning the generation and degradation of KDN-containing glycoconjugates. First, do free KDN-containing N-glycans accumulate as a result of insufficient degradation (e.g. insufficient lysosomal function) or overproduction of KDN-containing N-glycans, Thin dotted lines and the thick dotted line indicate the change after transfer of KDN by α2,6-sialyltransferase (abbreviated as 2,6-K) and α2,3-sialyltransferase (abbreviated as 2,3-K) to the desialylated products, respectively. In (B) and (C), mark Xs ( positions of standard glycans) are omitted, and two lines are curved so as not cross the irrelevant marks.
KDN-containing complex type N-glycans in prostate cancers which exceeds normal degradation capacity, leading to the accumulation of KDN-containing N-glycans? The former mechanism was proposed to be responsible for the accumulation of free Neu5Ac-containing N-glycans in human stomach cancer-derived cell lines, MKN7 and MKN45 cells (Ishizuka et al. 2008) . Our preliminary analysis of the structures of membrane-bound glycoprotein N-glycans of a couple of prostate cancer tissues, including the case shown in Figure 1A in which the levels of free Neu5Ac-and KDN-containing N-glycans were almost the same, may provide an important clue to answer this question. From these analyses, all the acidic N-glycans were composed of Neu5Ac-linked N-glycans, and no KDN-linked N-glycans have been observed in membranebound glycoprotein N-glycans, even though more than 99% of total acidic membrane-bound glycoprotein N-glycans was analyzed by MS 2 . These results suggest that the free KDN-containing N-glycans accumulate because of insufficient degradation, rather than overproduction.
The second question is whether sialidases that are able to cleave KDN linkages are present in human? In general, KDN linkages are resistant to the action of bacterial and viral sialidases, with one exception of that derived from Sphingobacterium multivorum . Sialidases that cleave both KDN and Neu5Ac linkages (KDN sialidases) have been reported in animals that contain rich KDN glycoconjugates, such as rainbow trout (Angata et al. 1994) . Currently, four kinds of human neuraminidases, Neu1 (lysosomal), Neu2 (cytosolic), Neu3 and Neu4 (both membrane-bound), are known to mediate the release of an Neu5Ac residue from sialoglyconjugates (Achyuthan and Achyuthan 2001; Monti et al. 2004) . KDN linkages are thought to be resistant to the action of human sialidases, because biochemical analyses revealed that mammalian Neu1, Neu2 and Neu4 could not cleave KDN linkages (Davies et al. 2012; Sato and Kitajima, unpublished results) . However, further studies will be needed to clarify the mechanism responsible for the preferential accumulation of free α2,6-linked KDN N-glycans and the preferential removal of the α6-Man arm of the N-glycan core structures.
The third question arising from our findings is why free KDN-containing N-glycans accumulate specifically in prostate cancers, but not in normal and cancerous tissues from the colon and pancreas? The abundance of KDN in prostate cancer tissues is thought to be very low, probably less than 1% of total sialic acid content according to our structural analyses of membrane-bound glycoprotein N-glycans. Nonetheless, the level of KDN in prostate cancer tissues might be higher than that of other tissues. The formation of KDN monosaccharide appears to be one of the key factors limiting the biosynthesis of KDN-containing glycoconjugates. Cellular levels of free KDN were found to increase when mouse melanoma B16 and COS-7 cells were cultured in mannose-rich media (mannose being a precursor in the de novo synthesis of KDN) and when human cancer cell lines, HeLa, LS174T and Caco-2 cells, were cultured under hypoxic conditions that mimic the microenvironment inside tumor tissues (Angata et al. 1999; Go et al. 2007 ). Indeed, specific conditions, such as the hypoxic microenvironment found in prostate cancers, might lead to an increase in the cellular KDN levels.
A defect in glycoprotein degradation by loss of lysosomal glycosidase activity in inherited diseases, such as sialidosis and fucosidosis, leads to the accumulation of partially degraded fragments in tissues and the appearance of related fragments in the urine (Tsay et al. 1976; Strecker et al. 1977) . Three kinds of Neu5Ac-containing N-glycans that accumulate in prostate cancers, F3-2, F1 and F8, are present in the urine of patients with the lysosomal disease, sialidosis (Strecker et al. 1977 ). Hence, it is possible that the levels of free Neu5Ac-and KDN-containing N-glycans might be increased in the urine of prostate cancer patients.
In summary, this is the first study to report the identification and characterization of KDN as a glycoconjugate in human tissues. We have unequivocally demonstrated that substantial amounts of free KDN-containing complex-type N-glycans accumulate in prostate cancers. To evaluate free KDN-containing N-glycans as potential tumor markers, the levels of these oligosaccharides in the urine of prostate cancers and normal controls must be assessed. 
Materials and methods
All human tissue specimens were obtained from Osaka University Medical School-related hospital. This study was approved by the Local Ethics Committee of Osaka Medical Center for Cancer and Cardiovascular Diseases. Informed consent was obtained from each patient. Primary and metastatic prostate cancerous tissue samples were used in this study. Most of the samples were needle biopsies. Normal prostate tissues were not examined due to the difficulty of obtaining normal prostate tissues from biopsy samples. The majority of the experimental procedures used in this study have been reported previously, including the isolation of GSLs and free oligosaccharides, preparation and separation of PA-oligosaccharides and mass spectrometry analyses ). In brief, prostate cancer tissues were extracted with 1200 μL of chloroform/methanol (2:1, v/v), followed by 800 μL of chloroform/ methanol/water (1:2:0.8, v/v/v). This methodology extracts both GSLs and free oligosaccharides. The extracts were loaded onto a DEAE-Sephadex A25 column and flow-through fractions were collected as neutral oligosaccharides. Acidic oligosaccharides were subsequently eluted with 200 mM ammonium acetate in methanol. The neutral and acidic fractions were digested with recombinant endoglycoceramidase II from Rhodococcus Sp. (Takara Bio Inc., Shiga, Japan) to release the oligosaccharide portion from GSLs. Liberated oligosaccharides from GSLs and free oligosaccharides were then labeled with 2-AP (Natsuka and Hase 1998). PA-oligosaccharides were separated on a Shimadzu LC-20A HPLC system equipped with a Waters 2475 fluorescence detector. Normal-phase HPLC was performed on a TSK gel Amide-80 column (0.2 × 25 cm, Tosoh, Tokyo, Japan). The molecular size of each PA-oligosaccharide is given in glucose units (Gu) based on the elution times of PA-isomaltooligosaccharides. Reverse-phase HPLC was performed on a TSK gel octa decyl silyl (ODS)-80Ts column (0.2 × 15 cm, Tosoh). The retention time of each PA-oligosaccharide is given in Gu based on the elution times of PA-isomaltooligosaccharides. Thus, a given compound on these two columns provides a unique set of Gu (amide) and Gu (ODS) values, which correspond to coordinates of the 2D map. PA-oligosaccharides were analyzed by LC/ESI MS 2 according to our previously established procedures (Korekane et al. 2007 ).
Glycosidase digestions KDN-linked PA-oligosaccharides were digested with 2 U/mL of KDNase from S. multivorum, which specifically hydrolyzes deaminoneuraminyl but not N-acetylneuraminyl linkages, in 100 mM Tris-acetate buffer, pH 6.0 containing 100 mM NaCl and 0.1% bovine serum albumin for 16 h at 25°C Nishino et al. 1996) . PA-oligosaccharides were digested with 2 U/mL of α-sialidase from Arthrobacter ureafaciens (Nacalai, Nakagyo-ku, Kyoto, Japan) in 100 mM sodium acetate buffer, pH 5.5, for 2 h at 37°C.
